KLRA

Ribupatide oral global Phase 3 program expected to begin in 1H 2027 following completion of End-of-Phase 2 meeting with FDA Ribupatide injection Phase 2b trial and KaiNETIC global Phase 3 program fully enrolled; data expected mid-2027 and mid-2028, respectively Safiglipron (KAI-7535) global Phase 2 trial fully enrolled; data now anticipated mid-2027 KAI-4729 IND now active with U.S. FDA; on track to initiate Phase 1 single-dose injection site/ethnic bridging trial by the end of 2026 Cash continues to support execution of multiple clinical milestones with runway into mid-2028 WALTHAM, Mass., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Kailera Therapeutics, Inc. (Nasdaq: KLRA) (Kailera), a clinical-stage biotechnology company focused on elevating the next era of obesity care, today reported financial results for the third quarter ended September 30, 2026, and provided a summary of recent business highlights.

Ron Renaud, President and Chief Executive Officer, and additional members of the management team will participate in the following investor conferences

- New Phase 1 data highlight flexibility of injection site for ribupatide injection - Four additional oral presentations from Hengrui Pharma add to the clinical evidence behind Kailera's pipeline WALTHAM, Mass., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Kailera Therapeutics, Inc. (Nasdaq: KLRA) (Kailera), a clinical-stage biotechnology company focused on elevating the next era of obesity care, today announced Phase 1 data for ribupatide injection, a GLP-1/GIP receptor dual agonist currently advancing through global Phase 3 clinical trials, presented at the 62nd Annual Meeting of the European Association for the Study of Diabetes (EASD).

Kailera Therapeutics, Inc. targets the high-potential GLP-1 obesity market, leveraging a $718M IPO and a robust pipeline licensed from Hengrui. KLRA's lead candidate, ribupatide, shows competitive mean weight loss (23.6% at 36 weeks) and a favorable safety profile in ex-China studies. Despite a 40% post-IPO share price drop, KLRA's $1.65 bn valuation appears attractive given its late-stage pipeline and $900m cash balance.

WALTHAM, Mass., Sept. 16, 2026 (GLOBE NEWSWIRE) -- Kailera Therapeutics, Inc. (Nasdaq: KLRA) (Kailera), a clinical-stage biotechnology company focused on elevating the next era of obesity care, today announced participation in the following investor conferences: Bernstein Insights: Healthcare Leaders and Disruptors - 3rd Annual Healthcare Forum Wednesday, September 23, 2026, 9:40 a.m.

Kailera Therapeutics (NASDAQ:KLRA) closed most recently at $18.51, between a post-IPO high of $28.23 and low of $16.39, with a $2.40 billion market cap.

IND for ribupatide oral active with U.S. FDA, initiation of global Phase 3 obesity trials planned for the first half of 2027 Ribupatide injection Phase 2b high-dose trial in obesity fully enrolled, data anticipated in mid-2027 Expanded executive team to strengthen technical operations capabilities and corporate affairs leadership Cash, cash equivalents, and marketable securities expected to support execution of multiple clinical milestones with runway into mid-2028 WALTHAM, Mass., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Kailera Therapeutics, Inc. (Nasdaq: KLRA) (Kailera), a clinical-stage biotechnology company focused on elevating the next era of obesity care, today reported financial results for the second quarter ended June 30, 2026, and provided a summary of recent business highlights.

Kailera is building a multi-modal obesity franchise with exclusive global rights to Hengrui Pharma's obesity portfolio, leveraging late-stage assets and ongoing data. KLRA's robust cash position—over $1.3 billion post-IPO—funds operations through mid-2028, supporting multiple pivotal trial readouts before further capital is needed. Pipeline catalysts include global Phase 3 trials for ribupatide and promising Phase 2/3 data for oral GLP-1 candidates, targeting differentiated efficacy and convenience.

Kailera ​Therapeutics said ‌on ​Tuesday ​its GLP-1 ⁠drug ​for patients ​with diabetes ​and ​obesity met the ‌main ⁠goal of ​two-late ​stage ⁠trials.

Kailera Therapeutics, Inc., a clinical-stage biotechnology company focused on elevating the next era of obesity care, today announced the appointment of Ka